Overall survival (OS) and progression free survival (PFS) were different between KPNA2 high and low expression groups.<h4>Conclusions</h4>KPNA2 was widely dysregulated and mutated in carcinomas and correlated with the patients prognosis which may be potential target for cancer treatment and biomarker for prognosis. This evidence concerns the gene KPNA2 and carcinoma.